Congenital Neutropenia. Neutropenia
Conditions
Interventions
PegGCSF produced by Pouyesh Darou Prescribed weekly or every 2 weeks and the dose will be adjusted based on response to drug.
Sponsors
Pouyesh Darou biopharmaceutical Co.
Immunology, Asthma and Allergy research Institute
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients and children with severe congenital neutropenia over 12 years Severe Congenital Neutropenia Patients Myeloid maturation arrest in bone marrow Already successfully treated with Filgrastim Negative mutation in GCSF receptor Normal spleen and liver in abdominal sonography Consent to Participate in study and sign inform consent Cooperative patient for close follow-up
Exclusion criteria
Exclusion criteria: Secondary neutropenia due to chemotherapy or other diseases Life-threatening complications such as anaphylaxis or splenic rupture due to Filgrastim Uncooperative patient for close follow-up Severe Spleenomegaly patients with other chronic diseases such as heart or hepatic disease or ...
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute Neutrophil Count. Timepoint: first day of study , 7th day, 14th day, 21st day, 28th day, 35th day, 42nd day, 49th day, 56th day, 3th day, 70th day, 77th day, 84th day, 91st day then every month until reciving the drug. Method of measurement: Blood Sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Infection. Timepoint: Monthly. Method of measurement: Clinical questionnare.;Hospitalization rate. Timepoint: Monthly. Method of measurement: Clinical questionnare. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh Maddah
Immunology, Asthma and Allergy Research Institute
Outcome results
None listed